Professor Meng Zhiqiang | IMbrave150's OS results are "another success" and "T-A" opens a new chapter in HCC treatment

China is a "big country of liver cancer", China's annual liver cancer cases and deaths accounted for more than half of the world.
the emergence of immuno combination therapy, for liver cancer immunotherapy opened a "skylight."
shanghai, China, January 12, 2021 - Roche announces that it will officially report the latest results of the IMbrave 150 Research Total Survival (OS) at the American Society of Clinical Oncology (ASCO GI) this month: - After a 15.6-month follow-up period, AtiliJuju monolithic "The T-A" scheme reduces the risk of death by 34%, median OS reaches 19.2 months, - Median OS reaches 24.0 months in the Chinese sub-group, and non-progress lifetime (PFS), objective efficiency (ORR), etc., is consistent with the primary analysis results, and its safety is consistent with previously known safety characteristics of individual drug use, and no new safety signals have been found.
to this, the doctor had the honor to interview Professor Meng Zhiqiang, Director of the Minimally Invascopic Treatment Center of Fudan University Affiliated Oncology Hospital, to introduce us to the significance of the latest results of the IMbrave150 study for the treatment of hepatocellular carcinoma (HCC).
: As the PI of the IMbrave150 study in China, how were you feeling when you first learned about this median OS message? Professor Meng Zhiqiang: I was very happy when I learned of the OS results! Because most liver cancer in China is caused by hepatitis B virus infection, in past studies, the efficacy of Chinese patients is always "in the downwind", compared with other factors leading to liver cancer efficacy is worse.
and the IMbrave150 study found that liver cancer patients with a history of hepatitis B were more efficient when treated with a combined immunotherapy.
infection with hepatitis B virus can cause chronic long-term inflammatory response to the liver and is one of the root causes of liver cancer.
this process leads to changes in the local immuno-micro-environment, which may be more suitable for immuno-combined therapy.
in China, where patients with advanced liver cancer are the majority and have fewer effective treatments, we Chinese doctors are certainly very happy that there is finally a solution that works better for our patients.
: For a long time, OS in patients with advanced liver cancer was only about a year.
from a clinician's point of view, what do you think of the total survival of the "T-A" therapy in the IMbrave150 study for up to two years? Professor Meng Zhiqiang: Previously, liver cancer was called the "king of cancer" in China.
but with the development of medicine, the pattern of tumor treatment has changed a lot.
treatment methods gradually increased, liver cancer patients are no longer as difficult as before, the efficacy has also made significant progress.
, liver cancer has now successfully removed the "king of cancer" "hat."
the incidence of liver cancer in China is very high, especially in the advanced patients accounted for a relatively high.
now has a new treatment, the efficacy has improved, the patient's survival can be doubled, so this is a very big change, the shock is also great.
: Could you share how safe is the first-line treatment of patients with advanced hepatocellular carcinoma with the "T-A" combination therapy? What kind of exploration and demonstration do you think "T-A" can be used to make patients with advanced liver cancer both "live long" and "live well"? What do you think you should do in the future to create better conditions for the treatment and life of patients with advanced liver cancer? Professor Meng Zhiqiang: We know that if a treatment is not used safely as a basis, the efficacy can not be used for a long time.
, our ultimate goal is to control the development of the disease while keeping patients alive and well.
, for example, after the use of sorafini, hand-foot reaction syndrome is a very prominent adverse reaction, and there is no better solution, so some patients are reluctant to use it as a treatment option.
clinicians have previously worried about whether the union of the two drugs will lead to greater adverse reactions to the "T-A" program.
later, it was found that although the incidence of adverse reactions is not low, but the controllability of these adverse reactions is high, such as high blood pressure, drugs can be well controlled, will not have too much impact on the daily life of patients.
"Healthy China 2030" outline issued by China in 2016 mentioned that by 2030, the overall cancer survival rate should be increased by 15%.
liver cancer as a high incidence of tumors, how to improve survival to a new level is very important.
with the continuous progress of medical research, patients can live up to two years, so can it reach four to five years in the future? So it also requires the joint efforts of scientists and clinical experts to continuously explore and optimize the existing treatment options.
future, individualized therapy will be the most important direction of medical development.
it is critical to develop different treatment strategies for different patients.
is expected to improve patient survival through a number of initiatives.
: In 2020, the National Drug Administration (NMPA) approved the "T-A" combination therapy for the first-line treatment of advanced liver cancer, there are comments that "T-A" achieved the effect of 1-1>2, please introduce the reasons for this.
Meng Zhiqiang: "T-A" combination therapy for advanced liver cancer first-line treatment, involving basic research in tumor biology.
current research has found that anti-angiogenesic drugs can change the tumor's immune microenvironment, which is more suitable for the role of immuno-checkpoint inhibitors, so anti-angiogenesic drugs combined immuno-checkpoint inhibitors can do "1 plus 1 .gt;2."
In this article, Medical Pulse is authorized to reproduce Medical Pulse Source: Medical Pulse Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to reproduce by any media, website or individual, and must be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here